AdRTSIL-12 is a Gene Therapy owned by Alaunos Therapeutics, and is involved in 7 clinical trials, which were completed.

Ad-RTS-IL-12 (INXN 2001) is a DNA therapeutic which employs an adenoviral vector to deliver, directly into the patient’s cells, a gene which expresses IL-12. Adenoviral vector transfers genes based on adenovirus. Interleukin-12 is a pleiotropic cytokine, which is produced primarily by stimulated macrophages. IL-12 is a proinflammatory cytokine produced by phagocytic cells, B cells, and other antigen-presenting cells that modulate adaptive immune responses by favoring the generation of T-helper type 1 cells. IL-12 exerts a variety of biological effects on T and natural killer cells. IL-12 induced IFN-gamma acts in a positive feedback loop that represents an important amplifying mechanism in the inflammatory response.

The revenue for AdRTSIL-12 is expected to reach a total of $145m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the AdRTSIL-12 NPV Report.

AdRTSIL-12 is originated and owned by Alaunos Therapeutics.

AdRTSIL-12 Overview

Ad-RTS-IL-12 (INXN 2001) is under development for the treatment high-grade glioma, newly diagnosed recurrent or progressive glioblastoma, grade III malignant gliomas. The drug candidate is administered by intratumoral route. It is an adenovirus vector engineered to express hIL-12. Production of IL-12 within cells is tightly regulated by the RheoSwitch Therapeutic System (RTS), a gene switch controlled by an orally administered activator ligand (AL), veledimex (INXN-1001). It was also under development for metastatic melanoma, metastatic breast cancer, anaplastic astrocytoma, and colon cancer.

It was under development for the treatment of pediatric diffuse intrinsic pontine glioma.

Alaunos Therapeutics Overview

Alaunos Therapeutics formerly ZIOPHARM Oncology, is a provider of next-generation immune therapies. The company offers Controlled IL-12 and t-cell therapy to fight blood cancers and solid tumors. Its Controlled IL-12 platform provides therapy for cold tumors by turning them hot by activating an immune response. The company also provides Sleeping Beauty, a clinically-advanced non-viral cell therapy technology which helps in the manufacturing of genetically modified chimeric antigen receptors (CARs) and T-cell receptors (TCRs) targeting specific tumor-derived antigens. Its products and technologies are used in the treatment of hematologic malignancies, solid tumors and graft-versus-host-disease. The company is headquartered in Boston, Massachusetts, the US.

The company reported revenues of (US Dollars) US$0.4 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was US$77.6 million in FY2021, compared to an operating loss of US$80.4 million in FY2020. The net loss of the company was US$78.8 million in FY2021, compared to a net loss of US$80 million in FY2020.

Quick View – AdRTSIL-12

Report Segments
  • Innovator
Drug Name
  • AdRTSIL-12
Administration Pathway
  • Intratumor
Therapeutic Areas
  • Oncology
  • Undisclosed
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.